Zhiqiang Jing1, Liqing Kuang2, Yanping Wang3, Jiajia He3, Zilin Sun3, Naifeng Liu4,5, Jin Yang2. 1. Department of Physical Health, China Pharmaceutical University, Nanjing 210009, China. 2. Center of Drug Metabolism & Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, China. 3. Department & Institute of Endocrinology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China. 4. Department of Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China. 5. Department & Institute of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
Abstract
BACKGROUND: This study highlights the role of glycated hemoglobin (HbA1c), asymmetric demethylargine (ADMA) and N-ϵ-(carboxymethyl)-lysine (CML) in different periods of progress in Type 2 diabetes, and identifies a pathomechanism-based biomarker that is linked not only to the metabolic progresses but also to the underlying angiopathic progresses. METHODS: Peripheral blood samples from 100 healthy volunteers, 227 subjects with prediabetes, 173 subjects with Type 2 diabetes and 92 subjects with early diabetic microvascular complications were collected and analyzed for HbA1c, ADMA and CML. RESULTS: Compared to HbA1c and CML, ADMA is the strongest independent predictor and a significantly discriminative receiver operating characteristics profile, clearly distinguishing those with early diabetic microvascular complications. CONCLUSIONS: ADMA maybe serve as a pathomechanism-based biomarker, predicting the progression of microvascular complications.
BACKGROUND: This study highlights the role of glycated hemoglobin (HbA1c), asymmetric demethylargine (ADMA) and N-ϵ-(carboxymethyl)-lysine (CML) in different periods of progress in Type 2 diabetes, and identifies a pathomechanism-based biomarker that is linked not only to the metabolic progresses but also to the underlying angiopathic progresses. METHODS: Peripheral blood samples from 100 healthy volunteers, 227 subjects with prediabetes, 173 subjects with Type 2 diabetes and 92 subjects with early diabetic microvascular complications were collected and analyzed for HbA1c, ADMA and CML. RESULTS: Compared to HbA1c and CML, ADMA is the strongest independent predictor and a significantly discriminative receiver operating characteristics profile, clearly distinguishing those with early diabetic microvascular complications. CONCLUSIONS:ADMA maybe serve as a pathomechanism-based biomarker, predicting the progression of microvascular complications.